SSG
AVIR icon

Summit Securities Group’s Atea Pharmaceuticals AVIR Stock Holding History

Summit Securities Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,400
Closed -$14K – 576
2024
Q1 		$14K Buy
+3,400
New +$13.3K ﹤0.01% 328

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Summit Securities Group's AVIR Position: Q2 2024 in Review

Summit Securities Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 3,400 shares — an estimated $14K sold.

Summit Securities Group first reported a position in AVIR in Q1 2024 and held it in 1 quarter. The position peaked at $14K in Q1 2024. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • Summit Securities Group reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Summit Securities Group sold 3,400 Atea Pharmaceuticals shares in Q2 2024, an estimated $14K.
  • Summit Securities Group first reported a position in Atea Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Summit Securities Group's Atea Pharmaceuticals position peaked at $14K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Summit Securities Group's 13F filing for Q2 2024, filed 26 Jul 2024.